Strides Pharma Science Limited (Strides), a global pharmaceutical company, today announced the successful completion of the EU GMP inspection carried out by the National Institute of Pharmacy and Nutrition (OGYEI), Hungry at its Puducherry facility on April 28, 2021. 

The company has now received the renewed GMP (Good Manufacturing Practices) certificate thereby confirming the successful closure of the inspection. The Puducherry facility caters to the U.S., other regulated markets and Institutional businesses and has capabilities to produce finished dosage formulation products across multiple dosage formats.

Commenting on the development, Dr. R. Ananthanarayanan, Managing Director & CEO said, “We are pleased with the positive outcome of the recent EU GMP inspection at our Puducherry facility. The positive result of this inspection underscores our commitment to regulatory excellence at our global manufacturing sites. We stay focused on getting the facility reclassified with the USFDA.”

Strides mainly operates in the regulated markets and has an “in Africa for Africa” strategy along with an institutional business to service donor-funded markets. The company’s global manufacturing sites are located in India (Chennai, Puducherry and two locations in Bengaluru), Singapore, Italy (Milan), Kenya (Nairobi) and the United States (Florida). The company focuses on “difficult to manufacture” products that are sold in over 100 countries.